Hopes for precise pharmacological treatment strategies in breast cancer (BC) and triple-negative breast cancer (TNBC) have been raised by the development of next-generation sequencing technologies, since breast cancer is a heterogeneous disease with various molecular types (e.g., HER2 + and TRPN, or estrogen or progesterone receptor). Here, ERBB2 is linked to breast carcinoma.